From: Requirements for a lead compound to become a clinical candidate
Properties | Details |
---|---|
Chemical properties | Stable molecule |
 | Nonproblematic synthesis with potential for scale-up |
Pharmacological properties | Selective high-affinity binding to target binding site |
 | Selective and potent functional effect on target receptor molecule in vitro |
 | Effectiveness in animal model of targeted human indication |
Pharmacokinetics | Adequate bioavailability for selected route of administration |
 | Adequate half-life and biodistribution for intended use |
Safety and toxicity | Satisfactory profile for inhibition and induction of cytochrome P450 enzymes |
 | Absence of obvious cardiac toxicity (hERG binding) |
 | Absence of obvious toxicity in animal studies |